bullish
Strong 1H FY18 – Hemlibra Approval for Non-Inhibitors to Boost Sales.
409 Views24 Aug 2018 15:47
We reiterate our “Equal-weight” rating on the stock post 1H FY18 (YE Dec-18) earnings.
Chugai reported strong 1H FY18 sales (+12.8% to ¥1b) due to...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
x